Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and oth...
Neuland Laboratories reported revenue of 14.77 billion INR for fiscal year 2025, down 5.2% from fiscal year 2024, and net income of 2.60 billion INR. In Q2 2026 (the quarter ended September 30, 2025) revenue was 5.14 billion INR, up 65.4% from a year before. India was its largest region in fiscal year 2025, with 32% of revenue. Its market capitalization was 263.85 billion INR as of October 12, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 12, 2026.
No profile data available.